What is MS Phase 3 Study Laquinimod?
CATEGORY:
NCT00509145 is a completed randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of daily oral administration of laquinimod 0.6 mg in subjects with relapsing remitting multiple sclerosis. Other study names are MS-LAQ-301, EUDRACT 2007-003226-19.
Save up to 80% off your prescriptions!
We currently don't have enough shared data that is made public for this treatment.
Let's build this page together! When you share what it's like to have MS Phase 3 Study Laquinimod through your profile, those stories and data appear here too.
Common side effects
| Side effect | Patients | Percentage |
|---|---|---|
| Back pain | 1 |
Learn more about our community’s experience with MS Phase 3 Study Laquinimod
What are people saying about MS Phase 3 Study Laquinimod?
1
1
members have reported taking MS Phase 3 Study Laquinimod
Join the conversation and connect with people who have taken MS Phase 3 Study Laquinimod
Last updated: